Cell cycle re-entry of senescent breast cancer cells after CDK4/6 inhibition (CDK4/6i) constitutes a major source of disease ...

(5) Validation with Multiple Cell Lines: The research utilized multiple HR+/HER2- breast cancer cell lines (such as MCF-7, T47D, CAMA-1) and triple-negative breast cancer cell lines (such as ...

FDA approval of PATHWAY HER2 (4B5) test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow ...

29.7-39.4) with chemotherapy. Median DOR was 14.3 months (95% CI, 12.5-15.9) and 8.6 months (95% CI, 6.9-11.5), respectively. An exploratory analysis of patients with HER2-ultralow expression (n ...

5,7–10 In addition, lack of bystander activity of the T-DM1 catabolite may decrease the benefit of T-DM1 in tumors with low or heterogeneous HER2 expression. With a 7-year invasive disease ...

此外，NGS 还可以用于监测肿瘤的动态变化，如 HER2 扩增的变化，这对于评估治疗反应和预后具有重要意义 [7] 。 曲妥珠单抗主要通过结合 HER2 受体 ...

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER2 ...

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate ... Sales last year grew by a third to $1.7 billion and the drug ...

The FDA has approved Dato-DXd, a TROP2-directed ADC, for the treatment of patients with HR+, HER2– breast cancer that has been previously treated with systemic therapy. 1 This approval is supported by ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).